Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Osteoarthritis, Knee Clinical Trial

Official title:

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03477487
• Other study ID #: XT-150-1-0202
• Status: Completed
• Phase: Phase 1
• Start date: June 8, 2018
• Est. completion date: September 30, 2019

Study information

• Verified date: October 2019
• Source: Xalud Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the Treatment of Osteoarthritic Pain.

Description:

Phase 1 dose escalation study to evaluate the safety, tolerability, and efficacy of a plasmid DNA encoding a variant of human IL-10. This 6-month study will follow subjects with severe osteoarthritis of the knee. Safety labs, physical exams, and blood levels of the IL-10 variant will be assessed for tolerability and any adverse events associated with the treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: September 30, 2019
• Est. primary completion date: July 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Male or female, between 18 and 90 years of age, inclusive

2. Sufficiently severe OA of the knee to meet accepted criteria for knee arthroplasty

3. Free of intra-articular infection, or infection at the injection site.

4. Symptomatic disease because of osteoarthritis, defined as one or more of the following Visual Analog Scale of Pain Intensity (VASPI) scores:

1. a worst pain of at least 70 at any time during the preceding week (based on scale of 0 to 100, with 100 representing "pain as bad as you can imagine").

2. a worst stiffness of at least 70 at any time during the preceding week (based on a scale of 0 to 100, with 100 representing "stiffness as bad as you can imagine").

5. Stable analgesic regimen during the 4 weeks prior to enrollment.

6. Inadequate pain relief (minimum =5 mean on the Brief Pain Inventory-Severity Scale) lasting =3 months.

7. In the judgment of the Investigator, acceptable general medical condition

8. Life expectancy >6 months

9. Female subjects of child-bearing potential, and those <1 year post-menopausal, must be practicing effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm) or total abstinence from heterosexual intercourse for a minimum of 1 month before study drug administration and agree to continue prevention methods for 3 months after participation in the study is completed.

10. Male subjects who are heterosexually active and not surgically sterile must agree to use effective contraception, including abstinence, for the duration of the study and for 3 months after the study is completed.

11. Have suitable knee joint anatomy for intra-articular injection

12. Willing and able to return for the follow-up (FU) visits

13. Able to reliably provide pain assessment

14. Able to read and understand study instructions, and willing and able to comply with all study procedures

Exclusion Criteria:

1. 1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug, including double-stranded DNA, mannose, and sucrose

2. Subject plans knee arthroplasty within 4 months, irrespective of the outcome of the trial or other conservative therapies

3. High peri-procedural risks which in the judgment of the investigator preclude a safe knee injection procedure (e.g., poorly controlled diabetes, cardiac inadequacy such as NYHA class > II, G4 glomerular filtration rate [eGFR < 30 mL/min by Cockcroft-Gault])

4. Current treatment with immunosuppressives (steroid therapy equivalent to >10mg/day prednisone); or other strong immunosuppressant

5. History of systemic immunosuppressive therapy; steroids (equivalent to >10mg/day prednisone) in the last 3 months

6. Currently receiving systemic chemotherapy or radiation therapy for malignancy

7. Clinically significant hepatic disease as indicated by clinical laboratory results =3 times the upper limit of normal for any liver function test (e.g., aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase)

8. Severe anemia (Grade 3; hemoglobin <8.0 g/dL, <4.9 mmol/L, <80 g/L; transfusion indicated), uncontrolled coagulopathy (Grade 1, prolonged activated partial prothrombin time (aPTT) > upper limit of normal (ULN) to 1.5xULN), or bleeding diathesis, Grade 1 white cell counts (lymphocytes <LLN - 800/mm3; <LLN - 0.8 x 10e9 /L, neutrophils <LLN - 1500/mm3; <LLN - 1.5 x 10e9 /L)

9. Positive serology for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus within 4 weeks of commencing the study

10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental state that in the opinion of the Investigator will interfere with study participation

11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical treatments)

12. Current treatment with anticoagulants, other than low-dose aspirin, prescribed for new onset of symptoms in 3 months before screening visit.

13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1 year before the screening visit

14. Women who are pregnant or nursing

15. Use of any investigational drug or device within 1 month before enrollment or current participation in a trial that included intervention with a drug or device; or currently participating in an investigational drug or device study.

16. Any condition that, in the opinion of the Principal Investigator, could compromise the safety of the subject, the subject's ability to communicate with the study staff, or the quality of the data

Related Conditions & MeSH terms

• Osteoarthritis, Knee

Intervention

Biological:
• XT-150
Human IL-10 variant transgene in a plasmid DNA vector

Locations

Country	Name	City	State
United States	Neurovations (Napa Pain Institute)	Napa	California

Sponsors (1)

Lead Sponsor	Collaborator
Xalud Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Clinical, laboratory measures of safety by CTCAE v4.0	6 months
Secondary	Visual Analog Scale of Pain Intensity	Validated index of pain	6 months
Secondary	Knee Injury and Osteoarthritis Outcomes Scale	KOOS	6 months
Secondary	WOMAC	Western Ontario and McMasters University Osteoarthritis Index	6 Months
Secondary	Brief Pain Inventory	Measure of pain associated with osteoarthritis	6 months